Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


U.S. Medical Device Firm Pursues ISO 13485 Certification
News Update

Share on Stocktwits


With this move, this company aims for fast-tracked regulatory approval for its nitric oxide delivery system.

Nu-Med Plus Inc. (NUMD:OTC.MKTS) began the process of obtaining ISO 13485 certification ahead of filing for U.S. Food and Drug Administration approval of its nitric oxide delivery devices. ISO 13485 is a set of international standards for designing, developing and manufacturing medical devices.

"This is a significant undertaking that we plan will pay off with faster approval of our nitric oxide delivery devices by the FDA," says Jeff Robins, CEO. "With the FDA moving toward international harmonization of standards, we believe this strategic move will position Nu-Med for growth in the international markets as well."

Indeed, Nu-Med aims to ultimately sell its products globally.

With respect to the certification requirements, the company has, to date, established a quality management systems program and trained its personnel on it. Currently, it is establishing and documenting additional processes.

Once completed, an independent, third party will determine whether or not Nu-Med has successfully met the necessary conditions. If the company has, it could be granted ISO 13485 certification in Q4/18.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Nu-Med Plus. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe